WO2016074650A1 - Salts of (3r)-3-cyclopentyl-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile - Google Patents

Salts of (3r)-3-cyclopentyl-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile Download PDF

Info

Publication number
WO2016074650A1
WO2016074650A1 PCT/CZ2015/000133 CZ2015000133W WO2016074650A1 WO 2016074650 A1 WO2016074650 A1 WO 2016074650A1 CZ 2015000133 W CZ2015000133 W CZ 2015000133W WO 2016074650 A1 WO2016074650 A1 WO 2016074650A1
Authority
WO
WIPO (PCT)
Prior art keywords
acid
pyrrolo
pyrazol
cyclopentyl
pyrimidin
Prior art date
Application number
PCT/CZ2015/000133
Other languages
English (en)
French (fr)
Inventor
Ludek Ridvan
Violetta Kiss
Hana TOZICKOVA
Marcela Tkadlecova
Ondrej Dammer
Lukas KREJCIK
Original Assignee
Zentiva, K.S.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentiva, K.S. filed Critical Zentiva, K.S.
Priority to EP15797582.2A priority Critical patent/EP3218379A1/en
Priority to EA201790985A priority patent/EA201790985A1/ru
Publication of WO2016074650A1 publication Critical patent/WO2016074650A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Definitions

  • the present invention relates to a novel salt of (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3- d]pyrimidin-4-yl ⁇ pyrazol-l-yl]propanenitrile of Formula I
  • the present invention relates to a pharmaceutically acceptable salt of (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-l-yl]propanenitrile and one acid component selected from the group consisting of benzoic acid, benzenesulphonic acid, 4-chlorobenzenesulphonic acid, citric acid, ethanesulphonic acid, fumaric acid, hydrobromic acid, hydrochloric acid, 2-naphthalenesulphonic acid, L-tartaric acid and p-toluenesulphonic acid.
  • the invention also relates to processes of preparation of salts as well as to their use in pharmaceutical compositions.
  • Use of solid forms of ruxolitinib and manufactured salts in the preparation of (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-l- yl]propanenitrile in the free form or in the form of any pharmaceutical salt thereof is also part of the invention.
  • WO2007070514 describes protein kinase inhibitors with valuable pharmacological effect in the treatment of related diseases.
  • One example of the compounds disclosed is (3R)-3- cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-l-yl]propanenitrile. Preparation of the base is also described.
  • the object of the present invention is to provide novel pharmaceutically acceptable salts of (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4"yl)pyrazol-l-yl]propanenitrile and one acid component selected form the group consisting of benzoic acid, benzenesulphonic acid, 4-chlorobenzenesulphonic acid, citric acid, ethanesulphonic acid, fumaric acid, hydrobromic acid, hydrochloric acid, 2-naphthalenesulphonic acid, L-tartaric acid and p-toluenesulphonic acid in amorphous form and methods of their production.
  • These salts can be used to prepare ruxolitinib salts and to prepare formulation thereof.
  • novel salts of ruxolitinib are as follows:
  • ruxolitinib and ruxolitinib salts consists in their good physical and chemical characteristics, which make them suitable for preparation of a dosage form.
  • these salts are easily producible by a 1-step method in polar aprotic solvents, preferebly in acetonitrile, methanol and ethanol with an excellent chemical purity.
  • polymorph The ability of a compound to crystallize in different crystalline phases is called polymorphism.
  • polymorph may include the amorphous phase (disordered), hydrates (water present in the crystal lattice) and solvates (solvents other than water present in the crystal lattice).
  • the difference in the crystal lattice of the crystalline modifications of a compound is expressed in different crystal symmetry and unit cell parameters which appears as the X-Ray diffraction characteristics of a crystalline powder.
  • the different crystalline modifications generate different set of angles and different values of the intensity and fmnaly result in different X-Ray powder diffractogram.
  • Amorphous phases lack the long-range order characteristic of a crystal. The absence of crystallinity is easily observed in an X-Ray powder diffractogram. Therefore, the X-Ray Powder Diffractogram can be used to identify different crystalline modifications as well as the amorphous phase.
  • the term ruxolitinib salts referes to ruxolitinib salts, as used in this patent application, is synonymous to commonly used expressions tiltamorphous ruxolitinib salts".
  • the term fluffyroom temperature is defined as a temperature between 15°C and 30°C; preferably it is between 20-25°C or about 25°C.
  • the present invention further relates to pharmaceutical formulations comprising one of the novel salts of (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-l- yl]propanenitrile and to the use thereof for the treatment of myelofibrosis.
  • Figure 1 is an FTIR spectra of the salt of (3R)-3-cyclopentYl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin- 4-yl)pyrazol-l-yl]propanenitrile and benzoic acid prepared according to Example 1;
  • Figure 2 is a 1H-NMR spectra of the salt of (3R)-3-cyclopentyl-3-[4- ⁇ 7H-pyrrolo[2,3- d]pyrimidin-4-yl)pyrazol-l-yl]propanenitrile and benzoic acid prepared according to Example l;
  • Figure 3 is a solid state NMR pattern of the salt of (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3- d]pyrimidin-4-yl)pyrazol-l-yl]propanenitrile and benzoic acid prepared according to Example
  • Figure 4 is an XRPD pattern of the salt of (3R)-3-cyclopentyl-3-[4- ⁇ 7H-pyrrolo[2,3-d]pyrimidin- 4-yl)pyrazol-l-yl]propanenitrile and benzoic acid prepared according to Example 1;
  • Figure 5 is a DSC curve of the salt of (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4- yl)pyrazol-l-yl]propanenitrile and benzoic acid prepared according to Example 1;
  • Figure 6 is an FTIR spectra of the salt of (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin- 4-yl)pyrazol-l-yl]propanenitrile and benzenesulphonic acid prepared according to Example 2;
  • Figure 7 is a 1H-NMR spectra of the salt of (3R)-3-cyclopentyl-3-[4- ⁇ 7H-pynOlo[2,3- d]pyrimidin-4-yl)pyrazol-l-yl]propanenitrile and benzenesulphonic acid prepared according to Example 2;
  • Figure 8 is a solid state N R pattern of the salt of (3R)-3-cyclopentyl-3-[4-(7H-pYrrolo[2,3- d]pyrimidin-4-yl)pyrazol-l-yl]propanenitrile and benzenesulphonic acid prepared according to Example 2;
  • Figure 9 is an XRPD pattern of the salt of (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[23-d]pyrimidin- 4-yl)pyrazol-l-yl]propanenitrile and benzenesulphonic acid prepared according to Example 2;
  • Figure 10 is a DSC curve of the salt of (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4- yl)pyrazol-l-yl]propanenitrile and benzenesulphonic acid prepared according to Example 2;
  • Figure 11 is an FT1R spectra of the salt of (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin- 4-yl)pyrazol-l-yl]propanenitrile and 4-chlorobenzenesulphonic acid prepared according to Example 3;
  • Figure 12 is a 1H-N R spectra of the salt of (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3- d]pyrimidin-4-yl)pyrazol-l-yl]propanenitrile and 4-chlorobenzenesulphonic acid prepared according to Example 3;
  • Figure 13 is a solid state NMR pattern of the salt of (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3- d]pyrimid'in-4-yl)pyrazol-l-yl]propanenitrile and 4-chlorobenzenesulphonic acid prepared according to Example 3;
  • Figure 14 is an XRPD pattern of the salt of (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3- d]pyrimidin-4-yl)pyrazol-l-yl]propanenitrile and 4-chlorobenzenesulphonic acid prepared according to Example 3;
  • Figure 15 is a DSC curve of the salt of (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4- y!)pyrazol-l-yl]propanenitrile and 4-chlorobenzenesulphonic prepared according to Example 3;
  • Figure 16 is an FTIR spectra of the salt of (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin- 4-yl)pyrazol-l-yl]propanenitrile and citric acid prepared according to Example 4;
  • Figure 17 is a 1H-NMR spectra of the salt of (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3- d]pyrimidin-4-yl)pyrazol-l-yi]propanenitrile and citric acid prepared according to Example 4;
  • Figure 18 is a solid state NMR pattern of the salt of (3R)-3-cyclopentyI-3-[4-(7H-pyrrolo[2,3- d]pyrimidin-4-yl)pyrazol-l-yl]propanenitrile and citric acid prepared according to Example 4;
  • Figure 19 is an XRPD pattern of the salt of (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3- d]pyrimidin-4-yl)pyrazol-l-yl]propanenitrile and citric acid prepared according to Example 4;
  • Figure 20 is a DSC curve of the salt of (3R)-3-cyclopentyl-3-t4-(7H-pyrrolo[2,3-d]pyrimidin-4- y!)pyrazol-l-yl]propanenttrile and citric acid prepared according to Example 4;
  • Figure 21 is an FTIR spectra of the salt of (3R)-3-cyclopentyl-3-[4-(7H-pyrro!o[2,3-d]pyrimidin- 4-yl)pyrazol-l-yl]propanenitrile and ethanesulphonic acid prepared according to Example 5;
  • Figure 22 is a 1H-NMR spectra of the salt of (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3- d]pyrimidin-4-yl)pyrazol-l-yl]propanenitrile and ethanesulphonic acid prepared according to Example 5;
  • Figure 23 is a solid state NMR pattern of the salt of ⁇ 3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3- d]pyrimidin-4-yl)pyrazol-l-yl]propanenitrile and ethanesulphonic acid prepared according to Example 5;
  • Figure 24 is an XRPD pattern of the salt of (3R)-3-cyclopentyl-3-[4-(7H-pyrro!o[2,3- dIpyrimidin-4-yl)pyrazol-l-yl]propanenitrile and ethanesulphonic acid prepared according to Example 5;
  • Figure 25 is a DSC curve of the salt of (3R)-3-cydopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidirt-4- yl)pyrazol-l-yl]propanenitrile and ethanesulphonic prepared according to Example 5;
  • Figure 26 is an FTIR spectra of the salt of (3R)-3-cyclopentyl-3-[4- ⁇ 7H-pyrroloi2 / 3-d]pyrimidin- 4-y!)pyrazo!-l-yl]propanenitri!e and fumaric acid prepared according to Example 6;
  • Figure 27 is a 1H-NMR spectra of the salt of (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3- d]pyrimidin-4-yl)pyrazol-l-yl]propanenitrile and fumaric acid prepared according to Example 6;
  • Figure 28 is a solid state NMR pattern of the salt of (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3- d]pyrimidin-4-yl)pyrazol-l-yl]propanenitrile and fumaric acid prepared according to Example 6;
  • Figure 29 is an XRPD pattern of the salt of (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3- d]pyrimidin-4-yl)pyrazol-l-yl]propanenitrile and fumaric acid prepared according to Example 6;
  • Figure 30 is a DSC curve of the salt of (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4- yl)pyrazol-l-yl]propanenitrile and fumaric prepared according to Example 6;
  • Figure 31 is an FTIR spectra of the salt of (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin- 4-yl)pyrazol-l-yl]propanenitrile and hydrobromic acid prepared according to Example 7;
  • Figure 32 is a solid state NMR pattern of the salt of (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3- d]pyrimidin-4-yl)pyrazol-l-yl]propanenitrile and hydrobromic acid prepared according to Example 7;
  • Figure 33 is an XRPD pattern of the salt of (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3- d]pyrimidin-4-yl)pyrazol-l-yl]propanenitrile and hydrobromic acid prepared according to Example 7;
  • Figure 34 is a DSC curve of the salt of (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[23-d]pyrimidin-4- yl)pyrazol-l-yl]propanenitrile and hydrobromic acid prepared according to Example 7;
  • Figure 35 is an FTIR spectra of the salt of ⁇ 3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[23-d]pyrimidin- 4-yl)pyrazol-l-yl]propanenitrile and hydrochloric acid prepared according to Example 8;
  • Figure 36 is a solid state NMR pattern of the salt of (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3- d]pyrimidin-4-yl)pyrazol-l-yl]propanenitnle and hydrochloric acid prepared according to Example 8;
  • Figure 37 is an XRPD pattern of the salt of (3R)-3-cyclopentyl-3-[4- ⁇ 7H-pyrrolo[2,3- d]pyrimidin-4-yl)pyrazoH-yl]propanenitrile and hydrochloric acid prepared according to Example 8;
  • Figure 38 is a DSC curve of the salt of (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4- Yl)pyrazol-l-yl]propanenitrile and hydrochloric acid prepared according to Example 8;
  • Figure 39 is an FTIR spectra of the salt of (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[23-d]pyrimidin- 4-yl)pyrazol-l-yl]propanenitrile and 2-naphthalenesulphonic acid prepared according to Example 9;
  • Figure 40 is a 1H-NMR spectra of the salt of (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3- d]pyrimidin-4-Yl)pyrazol-l-yl]propanenitrile and 2-naphthalenesulphonic acid prepared according to Example 9;
  • Figure 41 is a solid state NMR pattern of the salt of (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3- d]pynrnidin-4-yl)pyrazol-l-yl]propanenitrile and 2-naphthalenesulphonic acid prepared according to Example 9;
  • Figure 42 is an XRPD pattern of the salt of (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3- d]pyrimidm-4-yl)pyrazol-l-Yl]propanenitrile and 2-naphthalenesulphonic acid prepared according to Example 9;
  • Figure 43 is a DSC curve of the salt of (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4- yl)pyrazol-l-yl]propanenitrile and 2-naphthalenesulphonic acid prepared according to Example 9;
  • Figure 44 is an FTIR spectra of the salt of (3R)-3-CYclopentyl-3-[4-(7H-pYrrolo[2,3-d]pYrimidin- 4-yl)pyrazol-l-yl]propanenitrile and L-tartaric acid prepared according to Example 10;
  • Figure 45 is a 1H-NMR spectra of the salt of (3R)-3-cyclopentyl-3-t4-(7H-pyrrolo[2,3- d]pyrimidin-4-yl)pyrazol-l-yl]propanenitrile and L-tartaric acid prepared according to Example 10;
  • Figure 46 is a solid state NMR pattern of the salt of (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3- d]pyrimidin-4-yl)pyrazol-l-yl]propanenitrile and L-tartaric acid prepared according to Example 10;
  • Figure 47 is an XRPD pattern of the salt of ⁇ 3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3- d]pyrimidin-4-yl)pyrazol-l-yl]propanenitrile and L-tartaric acid prepared according to Example 10;
  • Figure 48 is a DSC curve of the salt of (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4- yl)pyrazol-l-yl]propanenitrile and L-tartaric acid prepared according to Example 10;
  • Figure 49 is an FTIR spectra of the salt of (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin- 4-yl)pyrazol-l-yl]propanenitrile and p-totuenesulphonic acid prepared according to Example 11;
  • Figure 50 is a 1H-NMR spectra of the salt of (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3- d]pyrimidin-4-yl)pyrazol-l-yl]propanenitrile and p-toluenesulphonic acid prepared according to Example 11;
  • Figure 51 is a solid state NMR pattern of the salt of (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3- d]pyrimidin-4-yl)pyrazol-l-yl]propanenitrile and p-toluenesulphonic acid prepared according to Example 11;
  • Figure 52 is an XRPD pattern of the salt of (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3- d]pyrimidin-4-yl)pyrazol-l-yl]propanenitrile and p-toluenesulphonic acid prepared according to Example 11;
  • Figure 53 is a DSC curve of the salt of (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4- yl)pyrazol-l-yl]propanenitriie and p-toluenesulphonic acid prepared according to Example 11.
  • the aim of the present invention is to provide novel pharmaceutically acceptable salts of (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-l-yl]propanenitrile
  • inventive salts may exist in different solid forms with different internal structures (polymorphism), which may have different physico-chemical properties. Therefore, pure crystalline forms and pure amorphous phase can be prepared, as well as mixtures of different crystalline forms in any ratio or mixtures of crystalline form ⁇ s) with the amorphous form.
  • inventive salt formed from (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4- yl)pyrazol-l-yl]propanenitrile and at least one pharmaceutically acceptable acid component can be present in a crystalline form or in an amorphous form.
  • the salts may be in an anhydrous and/or a solvent-free form; or they may be in a hydrated or sol ated form.
  • All said salts can be prepared by the reaction of ⁇ 3R)-3-cyclopentyl-3-[4- ⁇ 7H-pyrrolo[2,3- d]pyrimidin-4-yl)pyrazo!-l-yl]propanenitrile with an acid selected from the group consisting of benzoic acid, benzenesu!phonic acid, 4-chlorobenzenesulphonic acid, citric acid, ethanesulphonic acid, fumaric acid, hydrobromic acid, hydrochloric acid, 2 ⁇ naphthalenesulphonic acid, L-tartaric acid and p-toluenesulphonic acid in a solvent selected from the group consisting of C1-C4 alkyl alcohols, acetates, ketones, nitriles and water and any of their mixtures, preferebly in methanol, ethanol, 2-propanol, acetone, acetonitrile, ethyl acetate, tetrahydrofuran and
  • a salt of (3R)-3-cyclopentyl-3-[4- ⁇ 7H-pyrrolot2,3-d]pyrimidin-4-yl)pyrazol-l-yl]propanenitrile and an acid component selected from the group consisting of benzoic acid, benzenesulphonic acid, 4-chlorobenzenesulphonic acid, citric acid, ethanesulphonic acid, fumaric acid, hydrobromic acid, hydrochloric acid, 2-naphthalenesulphonic acid, L-tartaric acid and p- toluenesulphonic acid can be obtained by a process comprising the following steps: a) dissolving (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazoM- yl]propanenitrile in C1-C4 alkyl alcohols, acetates, ketones, nitriles and water or any of their mixtures, preferably in
  • the salt of (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-l- yi]propanenitrile and benzoic acid can be characterized by FTIR and IH-NMR spectroscopy investigations.
  • Figure 1 shows the FTIR spectrum (Nicolet Nexus 670) comprising characteristic peaks at 3197, 3130, 2941, 2863, 2254, 1584, 867, 831, 707 and 604 cm "1 wavenumbers.
  • Figure 2 shows the IH-NMR (Bruker AVANCE 500) spectrum.
  • the salt of (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-l- yl]propanenitrile and benzoic acid has the characteristic XRPD pattern as shown in Figure 4.
  • the salt of (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-l- yl]propanenitrile and benzoic acid is an essentially amorhpous phase.
  • the salt of (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-l- yl]propanenitrile and benzenesulphonic acid can be characterized by FTIR and IH-NMR spectroscopy investgations.
  • Figure 6 shows the FTIR spectrum (Nicolet Nexus 670) comprising characteristic peaks at 3109, 2950, 2868, 2814, 2250, 1621, 1596, 1033, 729 and 610 cm "1 wavenumbers.
  • Figure 7 shows the IH-NMR (Bruker AVANCE 500) spectrum.
  • the salt of (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-l- yl]propanenitrile and benzenesulphonic acid has the characteristic solid state NMR (Bruker 400 WB) spectra as shown in Figure 8.
  • the salt of (3R)-3-cyc!opentyl-3-[4-(7H-pyrrolo[2 / 3-d]pyrimidin-4-yl)pyrazol-l- yljpropanenitrile and benzenesulphonic acid has the characteristic XRPD pattern as shown in Figure 9.
  • the salt of (S l-S-cycio entyl-S- ⁇ -tyH-pyrrolotZ ⁇ -dlpyrimidin ⁇ -yOpyrazol-l- y!]propanenitrile and benzenesulphonic acid is an essentially amorhpous phase.
  • the salt of (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-l- yl]propanenitrile and benzenesulphonic acid can be further described by thermal analytical method.
  • the salt of (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-l- yl]propanenitriie and 4-chlorobenzenesulphonic acid has the characteristic XRPD pattern as shown in Figure 14.
  • the salt of (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4- yl)pyrazol-l-yl]propanenitrile and 4-chlorobenzenesulphonic acid is an essentially amorhpous phase.
  • T 0 nset 152.8.
  • the salt of (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-Yl)pyrazol-l- yl]propanenitrile and citric acid can be characterized by FTIR and IH-NMR spectroscopy investgations.
  • Figure 16 shows the FTIR spectrum (Nicolet Nexus 670) comprising characteristic peaks at 3116, 2950, 2869, 2251, 1716, 1584, 1343, 815, 738 and 615 cm 1 waven umbers.
  • Figure 17 shows the IH-NMR (Bruker AVANCE 500) spectrum.
  • the salt of (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-l- yllpropanenitrile and citric acid has the characteristic XRPD pattern as shown in Figure 19.
  • the salt of (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2 i 3-d]pyrimidin-4-yl)pyrazol-l- yl]propanenitrile and citric acid is an essentially amorhpous phase.
  • the salt of (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-l- yl]propanenitrile and ethanesulphonic acid can be characterized by FTIR and IH-NMR spectroscopy investgations.
  • Figure 21 shows the FTIR spectrum (Nicolet Nexus 670) comprising characteristic peaks at 3108, 2947, 2869, 2812, 2249, 1620, 1596, 1153, 1034 and 740 cm "1 wavenumbers.
  • Figure 22 shows the IH-NMR (Bruker AVANCE 500) spectrum.
  • the salt of (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-l- yl]propanenitrile and ethanesulphonic acid has the characteristic XRPD pattern as shown in Figure 24.
  • the salt of (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-l- yl]propanenitrile and ethanesulphonic acid is an essentially amorhpous phase.
  • the salt of (3R)-3-cyctopentyl-3-[4-(7H-pyrrolo[2 ) 3-d]pyrimidin-4-yl)pyrazol-l- yl]propanenitrile and fumaric acid can be characterized by FTIR and IH-NMR spectroscopy tnvestgations.
  • Figure 26 shows the FTIR spectrum (Nicolet Nexus 670) comprising characteristic peaks at 3118, 2951, 2868, 2251, 1699, 1582, 1558, 1344, 1258 and 734 cm 1 wavenumbers.
  • Figure 27 shows the IH-NMR (Bruker AVANCE 500) spectrum.
  • the salt of (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazoi-l- yl]propanenitrile and fumaric acid has the characteristic solid state NMR (Bruker 400 WB) spectra as shown in Figure 28.
  • the salt of (3R)-3-cyclopenty!-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-l- yl]propanenitrile and fumaric acid has the characteristic XRPD pattern as shown in Figure 29.
  • the salt of (3R)-3-cyclopentyl-3-(4-(7H-pyrrolot2,3-d]pyrimidin-4-yl)pyrazof-l- yl]propanenitrile and hydrobromic acid can be characterized by FTIR spectroscopy investgation.
  • Figure 31 shows the FTIR spectrum (Nicolet Nexus 670) comprising characteristic peaks at 3065, 2944, 2866, 2797, 2250, 1613, 1584, 1338, 815 and 741 cm 1 wavenumbers.
  • the salt of (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-l- yllpropanenitrile and hydrobromic acid has the characteristic XRPD pattern as shown in Figure 33.
  • the salt of (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrtmidin-4-yl)pyrazol-l- yl]propanenitrile and hydrobromic acid is an essentially amorhpous phase.
  • the salt of (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-l- yl]propanenitrile and hydrochloric acid has the characteristic XRPD pattern as shown in Figure 37.
  • the salt of (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-l- yl]propanenitrile and hydrochloric acid is an essentially amorhpous phase.
  • the salt of (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[23-d]pyrimidin-4-yl)pyrazol-l- yl]propanenitrile and 2-naphthalenesulphonic acid can be characterized by FTIR and 1H-N R spectroscopy investgations.
  • Figure 39 shows the FTIR spectrum (Nicolet Nexus 670) comprising characteristic peaks at 3113, 2951, 2868, 2250, 1621, 1594, 1164, 1027, 816 and 673 cm 1 wavenumbers.
  • Figure 40 shows the 1H-N R (Bruker AVANCE 500) spectrum.
  • the salt of ⁇ 3R)-3-cyclopentyl-3-[4- ⁇ 7H-pyrro!o[2,3-d]pyrimidin-4-yl)pyrazol-l- yl]propanenitrile and 2-naphthalenesulphonic acid has the characteristic XRPD pattern as shown in Figure 42.
  • the salt of (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimid " in-4- yl)pyrazol-l-yl]propanenitrile and 2-naphthalenesulphonic acid is an essentially amorhpous phase.
  • the salt of (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-l- yllpropanenitrile and L-tartaric acid can be characterized by FTIR and 1H-NMR spectroscopy investgations.
  • Figure 44 shows the FTIR spectrum (Nicolet Nexus 670) comprising characteristic peaks at 3118, 2947, 2866, 2250, 1718, 1583, 1122, 1075, 816 and 737 cm "1 wavenumbers.
  • Figure 45 shows the 1H-NMR (Bruker AVANCE 500) spectrum.
  • the salt of (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-l- yllpropanenitrile and L-tartaric acid has the characteristic XRPD pattern as shown in Figure 47.
  • the salt of (3R)-3-CYClopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-l- yl]propaneriitrile and L-tartaric acid is an essentially amorhpous phase.
  • )pyrazol-l- yl]propanenitrile and p-toluenesulphonic acid can be characterized by FTIR and IH-NMR spectroscopy investgations.
  • Figure 49 shows the FTIR spectrum (Nicolet Nexus 670) comprising characteristic peaks at 3109, 2950, 2867, 2250, 1620, 1596, 1162, 1008, 680 and 564 cm '1 wavenumbers.
  • Figure 50 shows the IH-N (Bruker AVANCE 500) spectrum.
  • the salt of (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-l- yl]propanenitrile and p-toluenesulphonic acid has the characteristic XRPD pattern as shown in Figure 52.
  • -l- yl]propanenitrile and p-toluenesulphonic acid is an essentially amorhpous phase.
  • Scan description scan type - gonio - measurement range 2 - 40 ⁇ 2 ⁇ step size 0.022 2 ⁇ step time: 300 s.
  • Incident beam optics programmable divergence slits (irradiated length 10 mm). 10 mm mask. 1/49 anti-scatter fixed slit, 0.02 rad Soller slits.
  • Diffracted beam optics X'Celerator detector, scanning mode, active length 2.122 ⁇ , 0.02 rad Soller slits, anti-scatter slit 5.0 mm. Ni filter.
  • the temperatures specified in relation to DSC analyses are the temperatures of the peak maxima (T peak ) and onset temperature (T 0 nset) of peaks for the crystalline form and a glass transition temperature (Tg) of the amorphous form.
  • the enthalpy is given in J/g.
  • the weight of the sample was about 1.5-4.5 mg.
  • the suspensions was stirred at room temperature overnight and then filtered and dried with vacuum suctio .
  • the sligthly yellowish powder obtained was analyzed by FTIR spectroscopy.
  • the suspensions was stirred at room temperature overnight and then filtered and dried with vacuum suction.
  • HPLC purity 99.1% The sligthly yellowish powder obtained was analyzed by FT1R spectroscopy.
  • the sligthly yellowish powder obtained was analyzed by FTIR spectroscopy.
  • the sligthly yellowish powder obtained was analyzed by FTIR spectroscopy.
  • the suspensions was stirred at room temperature overnight and then filtered and dried with vacuum suction.
  • the sligthly yellowish powder obtained was analyzed by FTIR spectroscopy.
  • the sligthly yellowish powder obtained was analyzed by FTIR spectroscopy.
  • the suspensions was stirred at room temperature overnight and then filtered and dried with vacuum suction.
  • the sligthly yellowish powder obtained was analyzed by FT1R spectroscopy. Similarly, the same result was obtained using any of the recrystallization solvents listed in the Table 7.
  • the suspensions was stirred at room temperature overnight and then filtered and dried with vacuum suction.
  • the sligthly yellowish powder obtained was analyzed by FTIR spectroscopy.
  • the sligthly yellowish powder obtained was analyzed by FTIR spectroscopy.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PCT/CZ2015/000133 2014-11-10 2015-11-05 Salts of (3r)-3-cyclopentyl-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile WO2016074650A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP15797582.2A EP3218379A1 (en) 2014-11-10 2015-11-05 Salts of (3r)-3-cyclopentyl-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile
EA201790985A EA201790985A1 (ru) 2014-11-10 2015-11-05 Новые соли (3r)-3-циклопентил-3-[4-(7h-пирроло[2,3-d]пиримидин-4-ил)пиразол-1-ил]пропаннитрила

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CZ2014-773A CZ2014773A3 (cs) 2014-11-10 2014-11-10 Soli (3R)-3-cyklopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propannitrilu
CZPV2014-773 2014-11-10

Publications (1)

Publication Number Publication Date
WO2016074650A1 true WO2016074650A1 (en) 2016-05-19

Family

ID=54608211

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CZ2015/000133 WO2016074650A1 (en) 2014-11-10 2015-11-05 Salts of (3r)-3-cyclopentyl-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile

Country Status (4)

Country Link
EP (1) EP3218379A1 (cs)
CZ (1) CZ2014773A3 (cs)
EA (1) EA201790985A1 (cs)
WO (1) WO2016074650A1 (cs)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017008772A1 (en) * 2015-07-14 2017-01-19 Zentiva, K.S. Crystalline forms of (3r)-3-cyclopentyl-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile salts and preparation thereof
US11066403B2 (en) 2017-06-07 2021-07-20 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Solid form of azetidine derivative and preparation method therefor and use thereof
WO2023087101A1 (en) * 2021-11-19 2023-05-25 Apotex Inc Salts of ruxolitinib and crystalline forms thereof
WO2024028193A1 (en) 2022-08-03 2024-02-08 Medichem, S.A. Stable oral pharmaceutical formulation containing ruxolitinib hemifumarate
WO2024099396A1 (zh) * 2022-11-11 2024-05-16 浙江奥翔药业股份有限公司 芦可替尼晶体及其药物组合物

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4491175A1 (en) 2023-07-10 2025-01-15 Genepharm S.A. A solid oral composition of ruxolitinib

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007070514A1 (en) 2005-12-13 2007-06-21 Incyte Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
WO2008157208A2 (en) 2007-06-13 2008-12-24 Incyte Corporation Salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
WO2010083283A2 (en) 2009-01-15 2010-07-22 Incyte Corporation Processes for preparing jak inhibitors and related intermediate compounds
WO2011146808A2 (en) * 2010-05-21 2011-11-24 Incyte Corporation Topical formulation for a jak inhibitor
WO2012174061A1 (en) * 2011-06-14 2012-12-20 Novartis Ag Combination of panobinostat and ruxolitinib in the treatment of cancer such as a myeloproliferative neoplasm

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007070514A1 (en) 2005-12-13 2007-06-21 Incyte Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
WO2008157208A2 (en) 2007-06-13 2008-12-24 Incyte Corporation Salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
WO2010083283A2 (en) 2009-01-15 2010-07-22 Incyte Corporation Processes for preparing jak inhibitors and related intermediate compounds
US20100190981A1 (en) * 2009-01-15 2010-07-29 Jiacheng Zhou Processes for preparing jak inhibitors and related intermediate compounds
WO2011146808A2 (en) * 2010-05-21 2011-11-24 Incyte Corporation Topical formulation for a jak inhibitor
WO2012174061A1 (en) * 2011-06-14 2012-12-20 Novartis Ag Combination of panobinostat and ruxolitinib in the treatment of cancer such as a myeloproliferative neoplasm

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BERGE S M ET AL: "Pharmaceutical Salts", JOURNAL OF PHARMACEUTICAL SCIENCES, AMERICAN PHARMACEUTICAL ASSOCIATION, WASHINGTON, US, vol. 66, no. 1, 1 January 1977 (1977-01-01), pages 1 - 19, XP002550655, ISSN: 0022-3549, [retrieved on 20060918], DOI: 10.1002/JPS.2600660104 *
DATABASE PubChem Compound [online] NCBI; 12 February 2015 (2015-02-12), XP002752247, Database accession no. CID 87376673 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017008772A1 (en) * 2015-07-14 2017-01-19 Zentiva, K.S. Crystalline forms of (3r)-3-cyclopentyl-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile salts and preparation thereof
US11066403B2 (en) 2017-06-07 2021-07-20 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Solid form of azetidine derivative and preparation method therefor and use thereof
WO2023087101A1 (en) * 2021-11-19 2023-05-25 Apotex Inc Salts of ruxolitinib and crystalline forms thereof
WO2024028193A1 (en) 2022-08-03 2024-02-08 Medichem, S.A. Stable oral pharmaceutical formulation containing ruxolitinib hemifumarate
WO2024099396A1 (zh) * 2022-11-11 2024-05-16 浙江奥翔药业股份有限公司 芦可替尼晶体及其药物组合物

Also Published As

Publication number Publication date
EP3218379A1 (en) 2017-09-20
CZ2014773A3 (cs) 2016-05-18
EA201790985A1 (ru) 2017-08-31

Similar Documents

Publication Publication Date Title
EP3218379A1 (en) Salts of (3r)-3-cyclopentyl-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile
WO2017125097A1 (en) Crystalline forms of (3r)-3-cyclopentyl-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4- yl)pyrazol-l-yl]propanenitrile salts and preparation thereof
US11332467B2 (en) Solid state forms of palbociclib dimesylate
EP3322709B1 (en) Crystalline forms of (3r)-3-cyclopentyl-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile salts and preparation thereof
EP3344607A1 (en) Solid state forms of selexipag
AU2016239028B2 (en) P-toluenesulfonate for MEK kinase inhibitor, and crystal form thereof and preparation method therefor
WO2015067224A1 (en) Salts of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2-(pyridin-2-yl)ethanyl] indazole
AU2020220512A1 (en) FGFR inhibitor compound in solid form and preparation method therefor
WO2015085972A1 (en) NOVEL SALTS OF 3-(2-IMIDAZO[1,2-b]PYRIDAZIN-3-YLETHYNYL)-4-METHYL-N-[4-[(4-METHYL- 1-PIPERAZINYL)METHYL]-3-(TRIFLUOROMETHYL)PHENYL] BENZAMIDE
EP3321267A1 (en) Crystalline forms of 2-[1-ethylsulfonyl-3-[7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile salts and preparation thereof
WO2015068055A1 (en) Crystalline dasatinib process
WO2018113801A1 (en) Crystalline forms of2-[1-ethylsulfonyl-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile with phosphoric acid and a method of their preparation
WO2017032349A1 (en) Salts of 5-fluoro-3-phenyl-2-[(1s)-1-(9h-purin-6-ylamino)propyl]quinazolin-4-one and preparation thereof
EP3546456B1 (en) Crystal of pyrido[3, 4-d]pyrimidine derivative or solvate thereof
WO2015085973A1 (en) Modifications of 3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-[4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl] benzamide hydrochloride salt
WO2012125993A1 (en) Solid state forms of rilpivirine base, and rilipivirine salts
WO2015085971A1 (en) Hydrobromide salt of 3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-[4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl] benzamide
WO2014173377A2 (en) New crystalline forms of apixaban and a method of their preparation
CN108718526B (zh) 尼达尼布盐的结晶变态和其制备方法
WO2016188506A1 (en) Solid forms of 5-fluoro-3-phenyl-2-[(1s)-1-(9h-purin-6-ylamino)propyl]quinazolin-4-one and preparation thereof
WO2015169269A1 (en) Salts of 2-chloro-n-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide
RU2793759C2 (ru) Кристаллическая форма пиридо[3,4-d]пиримидинового производного
SK50262014U1 (sk) Farmaceuticky prijateľné soli 2-chlór-N-(4-chlór-3-(pyridín-2- yl)fenyl)-4-(metylsulfonyl)benzamidu

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15797582

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2015797582

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 201790985

Country of ref document: EA